Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.
about
Equipping the American Joint Committee on Cancer staging for resectable pancreatic ductal adenocarcinoma with tumor grade: a recursive partitioning analysisSEOM Clinical Guideline for the treatment of pancreatic cancer (2016).Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection.Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma.Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis.Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms.Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3.Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.Extrapancreatic perineural invasion in pancreatic adenocarcinoma.Duodenal invasion by pancreatic adenocarcinoma: MDCT diagnosis of an aggressive imaging phenotype and its clinical implications.Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis.Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis.Pancreatocolonic fistulization secondary to pancreatic adenocarcinoma presenting as unexplained halitosis.Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy.Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic cancer patients after radical resection and adjuvant chemotherapy.Pancreatic cancer survival analysis defines a signature that predicts outcomeA Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes RatioProposal of a modified American Joint Committee on Cancer staging scheme for resectable pancreatic ductal adenocarcinoma with a lymph node ratio-based N classification: A retrospective cohort studyA Prognostic Nomogram for Disease-Specific Survival in Patients with Pancreatic Ductal Adenocarcinoma of the Head of the Pancreas Following Pancreaticoduodenectomy
P2860
Q36161168-462B643A-882B-44D8-94BD-8B6B76449851Q37475173-ADF83695-5DA1-4A48-86BE-871237D2351DQ38631546-51CF4BB3-1A06-4488-A561-3990DA5C11EDQ40056869-9786123F-6E2B-4F1D-9C05-A5869C34C856Q40160341-8C41D7C4-CFB7-4090-8A13-51B93EC0B014Q41592795-C2A27505-2415-4C5E-9DB4-D11C1942CDA6Q41721785-661CF168-50E3-4542-A3EC-BDED601D736BQ42777537-60003903-B14E-4226-9362-13EEF412523DQ45304734-4F98F5BB-2281-4462-BB6B-C82F8C02AA10Q47109220-686F9401-EB92-4296-9CE5-9200433D68F3Q47192478-304EC7DF-9722-4973-964B-C33DB9CDC96BQ47361459-9E2086DE-96F6-49AA-9512-B19B26EBCC7CQ47550867-F6C529E5-A3D8-4566-8222-BC6D5AB84A83Q47713578-1BF67B2C-FAC4-4976-9F19-0685CE0B2F4AQ47749335-BE9CD24B-70C6-4980-8314-A765CBE9D0F8Q47808198-4108A32E-E189-4D08-B0B8-A45F4076AE34Q48143840-E5043592-A960-444D-8E91-B7BE296993C3Q50024624-C49B0DBA-7478-4981-87AE-37ED7C4E0CBDQ55328891-55779783-44BB-41F8-AC52-732A101E1E50Q55401908-0B8837F0-3960-4E0D-856B-5770E8F1A544Q55614259-BFC504BC-2524-4493-8365-224DD25ACEDEQ57136038-E7BB7656-CBDE-4B3D-9D9E-78BB1AB77D11Q57493796-3B9A17EF-FD7F-4267-968F-6A3608923E9FQ58706746-9A5A3CA5-B00B-4C0B-97CB-39B93CA80898Q58753879-46C93AC3-B89A-4B71-9850-48EE07A3BFA0
P2860
Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Multi-institutional Validation ...... ith Pancreatic Adenocarcinoma.
@en
type
label
Multi-institutional Validation ...... ith Pancreatic Adenocarcinoma.
@en
prefLabel
Multi-institutional Validation ...... ith Pancreatic Adenocarcinoma.
@en
P2093
P2860
P50
P1433
P1476
Multi-institutional Validation ...... ith Pancreatic Adenocarcinoma.
@en
P2093
Christopher L Wolfgang
Cristina R Ferrone
David S Klimstra
Deborah Kuk
John L Cameron
Keith D Lillemoe
Matthew J Weiss
Peter J Allen
P2860
P304
P356
10.1097/SLA.0000000000001763
P407
P50
P577
2016-05-09T00:00:00Z